Trials / Unknown
UnknownNCT05439824
A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Participants Aged 18 Years or More
A Randomized, Observer-blinded, Placebo-Controlled Phase 2 Clinical Study to Evaluate the Immunogenicity and Safety of a SARS-CoV-2 mRNA Vaccine (SYS6006) in Healthy Participants Aged 18 Years or More
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 450 (actual)
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This is a phase 2, randomized, observer-blinded, placebo-controlled clinical study to evaluate the immunogenicity and safety of SARS-CoV-2 mRNA Vaccine (SYS6006）in healthy participants aged 18 or more.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | SYS6006 20 μg | SARS-CoV-2 mRNA Vaccine |
| BIOLOGICAL | SYS6006 30 μg | SARS-CoV-2 mRNA Vaccine |
| BIOLOGICAL | Placebo | Placebo |
Timeline
- Start date
- 2022-06-28
- Primary completion
- 2023-01-12
- Completion
- 2023-06-28
- First posted
- 2022-06-30
- Last updated
- 2023-05-24
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05439824. Inclusion in this directory is not an endorsement.